Onconova Therapeutics, Inc. (ONTX)
(Delayed Data from NSDQ)
$4.07 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.07 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Stevanato Group (STVN) Q3 Earnings Meet Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 0% and 3.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of -2.22% and 27.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -3.70% and 6.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 130% and 18.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -23.81% and 5%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
by Zacks Equity Research
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
by Zacks Equity Research
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -40% and 6.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
by Zacks Equity Research
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.
Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Onconova (ONTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Onconova (ONTX) stock based on the movements in the options market lately.
Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer
by Zacks Equity Research
Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.
Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 3.57% and 35.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Onconova Therapeutics, Inc. (ONTX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Onconova Therapeutics, Inc. (ONTX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.
Jazz Pharma's Xywav Succeeds in Idiopathic Hypersomnia Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares rise.